Inhaled voriconazole for prevention of invasive pulmonary aspergillosis

Justin A. Tolman, Nathan P. Wiederhold, Jason T. McConville, Laura K. Najvar, Rosie Bocanegra, Jay I. Peters, Jacqueline J. Coalson, John R. Graybill, Thomas F. Patterson, Robert O. Williams

Research output: Contribution to journalArticle

28 Scopus citations

Abstract

Targeted airway delivery of antifungals as prophylaxis against invasive aspergillosis may lead to high lung drug concentrations while avoiding toxicities associated with systemically administered agents. We evaluated the effectiveness of aerosolizing the intravenous formulation of voriconazole as prophylaxis against invasive pulmonary aspergillosis caused by Aspergillus fumigatus in an established murine model. Inhaled voriconazole significantly improved survival and limited the extent of invasive disease, as assessed by histopathology, compared to control and amphotericin B treatments.

Original languageEnglish (US)
Pages (from-to)2613-2615
Number of pages3
JournalAntimicrobial agents and chemotherapy
Volume53
Issue number6
DOIs
StatePublished - Jun 1 2009

    Fingerprint

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Tolman, J. A., Wiederhold, N. P., McConville, J. T., Najvar, L. K., Bocanegra, R., Peters, J. I., Coalson, J. J., Graybill, J. R., Patterson, T. F., & Williams, R. O. (2009). Inhaled voriconazole for prevention of invasive pulmonary aspergillosis. Antimicrobial agents and chemotherapy, 53(6), 2613-2615. https://doi.org/10.1128/AAC.01657-08